Category: Xeljanz


In July of 2019, the Food and Drug Administration (FDA) approved a new boxed warning for Xeljanz and Xeljanz XR regarding the risks of blood clots and potential death for users of the drug. Manufacturers of Xeljanz were previously made aware that the use of the drug at higher doses could result in serious health […]